文献速递血液净化与透析慢性肾脏病

维持性血透患者由静脉维生素D类似物转为口服骨化三醇的结局

Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-02-28

本研究为回顾性队列研究,纳入2280例由静脉维生素D类似物转为口服骨化三醇的血透患者,匹配2280例继续静脉用药者。转口服后血钙、血磷较低而iPTH较高,但12个月时复合指标达标率两组均为45%,住院与生存无差异。

要点

  • 转口服骨化三醇后血钙、血磷下降,iPTH升高,但复合达标率与静脉组相当。
  • 两组住院率、住院时长及生存率无显著差异。
  • 在调整治疗分析和排除西那卡塞使用者后结果一致。

核心结论

  • 血透患者由静脉维生素D类似物转为口服骨化三醇后,矿物质代谢复合指标达标率与继续静脉用药者相似。

研究设计与样本

  • 回顾性队列研究,纳入Fresenius Kidney Care诊所成人血透患者,2280例转口服骨化三醇者匹配2280例继续静脉维生素D类似物者。
  • 随访至12个月,主要分析为意向性治疗,次要分析为接受治疗分析。

主要发现

  • 转口服骨化三醇组平均血钙和血磷水平较静脉组低,而iPTH水平较高。
  • 12个月时复合实验室指标达标率(钙<10 mg/dl、磷3.0-5.5 mg/dl、iPTH 150-600 pg/ml)两组均为45%(P=0.96)。
  • 两组住院率、住院时长和生存率相当。
  • 接受治疗分析和排除使用西那卡塞者后,组间无显著差异。

关键数值与推荐

  • 复合实验室指标达标定义为血钙<10 mg/dl、血磷3.0-5.5 mg/dl、iPTH 150-600 pg/ml。
  • 12个月达标率口服骨化三醇组45% vs 静脉维生素D组45%(P=0.96)。

临床怎么用

  • 在维持性血透患者中,由静脉维生素D类似物转为口服骨化三醇后,需关注血钙、血磷下降及iPTH升高,但整体复合达标率与静脉用药相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In the United States, intravenous vitamin D analogs are the first-line therapy for management of secondary hyperparathyroidism in hemodialysis patients. Outside the United States, oral calcitriol (1,25-dihydroxyvitamin D3) is routinely used. We examined standard laboratory parameters of patients on in-center hemodialysis receiving intravenous vitamin D who switched to oral calcitriol. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective cohort study of adult patients treated within Fresenius Kidney Care clinics. During a 6-month period (December 2013 to May 2014), we identified patients on an intravenous vitamin D analog (doxercalciferol or paricalcitol) who switched to oral calcitriol and matched them to patients receiving an intravenous vitamin D analog. Mean serum calcium, phosphate, and intact parathyroid hormone (iPTH) concentrations were examined for up to 12 months of follow-up. We used Poisson and Cox proportional hazards regression models to examine hospitalization and survival rates. The primary analysis was conducted as intention-to-treat; secondary analyses included an as-treated evaluation. RESULTS: A total of 2280 patients who switched to oral calcitriol were matched to 2280 patients receiving intravenous vitamin D. Compared with patients on intravenous vitamin D, mean calcium and phosphate levels in the oral calcitriol group were lower after the change to oral calcitriol. In contrast, iPTH levels were higher in the oral calcitriol group. At 12 months, the percentage of patients with composite laboratories in target range (calcium <10 mg/dl, phosphate 3.0-5.5 mg/dl, and iPTH 150-600 pg/ml) were comparable between groups (45% versus 45%; P=0.96). Hospital admissions, length of hospital stay, and survival were comparable between groups. An as-treated analysis and excluding those receiving cinacalcet did not reveal significant between-group differences. CONCLUSIONS: Among patients receiving in-center hemodialysis who were switched to oral calcitriol versus those on an intravenous vitamin D analog, the aggregate of all mineral and bone laboratory parameters in range was largely similar between groups.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Thadhani RI, Rosen S, Ofsthun NJ, et al. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2020. PMID: 32111702. doi:10.2215/CJN.07960719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。